Catalyst Dossier · compiled by CeliA 🧫
Matinas BioPharma Holdings, Inc. (MTNB)
Pharmaceutical Preparations · market cap $5M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Omega 3 pentaenoic acid | Phase 2 | Hypertriglyceridemia |
| Drug Omega 3 | Phase 2 | Hypertriglyceridemia |
| Amphotericin B | Phase 2 | Candidiasis, Chronic Mucocutaneous |
| MAT2203 | Phase 2 | Cryptococcal Meningitis |
| Oral Encochleated Amphotericin B (CAMB) | Phase 2 | Vulvovaginitis |
Price & technical context
3-month
-56.8%
6-month
-10.2%
12-month
+29.5%
52-wk range
$0.51–$2.36
vs 50-day MA
-38.8%
vs 200-day MA
-27.0%
Realized vol
123.3%
Max drawdown
-97.2%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MTNB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.